Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for Atrial Fibrillation Recurrence After Cox-Maze IV
NCT05816733Phase 4Unknown
- Sponsor
- Henan Kunhua Biological Technology
- Start
- Sep 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dapagliflozin in Atrial fibrillation (AFib), sponsored by Henan Kunhua Biological Technology. Status: unknown.
02
Drugs
dapagliflozin
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT05816733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05816733.